CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-03 | Borgeson Blake Director | Sale 10b5-1 | −40,000 | $3.88 | $155K | 6,068,287 |
| 2026-10-06 | Borgeson Blake Director | Sale 10b5-1 | −50,000 | $4.84 | $242K | 6,108,287 |
| 2026-09-01 | Borgeson Blake Director | Sale 10b5-1 | −30,000 | $3.34 | $100K | 6,158,287 |
| 2026-08-04 | Borgeson Blake Director | Sale 10b5-1 | −30,000 | $3.25 | $98K | 6,188,287 |
| 2026-07-07 | Borgeson Blake Director | Sale 10b5-1 | −40,000 | $3.96 | $159K | 6,218,287 |
| 2026-06-17 | Borgeson Blake Director | Grant or award | +88,424 | 6,258,287 | ||
| 2026-06-02 | Borgeson Blake Director | Sale 10b5-1 | −30,000 | $3.68 | $110K | 6,169,863 |
| 2026-05-05 | Borgeson Blake Director | Sale 10b5-1 | −30,000 | $3.52 | $106K | 6,199,863 |
| 2026-04-07 | Borgeson Blake Director | Sale 10b5-1 | −30,000 | $3.10 | $93K | 6,229,863 |
| 2026-03-03 | Borgeson Blake Director | Sale 10b5-1 | −170,000 | $3.46 | $588K | 6,259,863 |
| 2026-02-03 | Borgeson Blake Director | Sale 10b5-1 | −220,000 | $4.20 | $924K | 6,429,863 |
| 2026-01-06 | Borgeson Blake Director | Sale 10b5-1 | −220,000 | $4.36 | $959K | 6,649,863 |
| 2025-12-02 | Borgeson Blake Director | Sale 10b5-1 | −220,000 | $4.37 | $961K | 6,869,863 |
| 2025-06-18 | Borgeson Blake Director | Grant or award | +22,016 | 7,089,863 | ||
| 2025-06-18 | Borgeson Blake Director | Grant or award · Stock Option (Right to Buy) | +44,031 | 44,031 | ||
| 2025-01-02 | Borgeson Blake Director | Grant or award | +1,734 | 7,067,847 | ||
| 2024-11-12 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $7.64 | $87K | 7,066,113 |
| 2024-10-29 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $6.72 | $77K | 7,077,560 |
| 2024-10-15 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $6.67 | $76K | 7,089,007 |
| 2024-10-01 | Borgeson Blake Director | Grant or award | +2,026 | 7,100,454 |
Page 1 of 2 · 39 trades